228 related articles for article (PubMed ID: 1383386)
1. Characterization of an Epstein-Barr virus receptor on human epithelial cells.
Birkenbach M; Tong X; Bradbury LE; Tedder TF; Kieff E
J Exp Med; 1992 Nov; 176(5):1405-14. PubMed ID: 1383386
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
Sinha SK; Todd SC; Hedrick JA; Speiser CL; Lambris JD; Tsoukas CD
J Immunol; 1993 Jun; 150(12):5311-20. PubMed ID: 8390533
[TBL] [Abstract][Full Text] [Related]
3. Detection of the complement (CD21)/Epstein-Barr virus receptor in human lacrimal gland and ocular surface epithelia.
Levine J; Pflugfelder SC; Yen M; Crouse CA; Atherton SS
Reg Immunol; 1990-1991; 3(4):164-70. PubMed ID: 1966579
[TBL] [Abstract][Full Text] [Related]
4. Stable expression and function of EBV/C3d receptor following genomic transfection into murine fibroblast L cells.
Cantaloube JF; Piechaczyk M; Calender A; Lenoir G; Minty A; Carrière D; Fischer E; Poncelet P
Eur J Immunol; 1990 Feb; 20(2):409-16. PubMed ID: 1690137
[TBL] [Abstract][Full Text] [Related]
5. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells.
Smith NA; Coleman CB; Gewurz BE; Rochford R
J Virol; 2020 May; 94(11):. PubMed ID: 32238579
[TBL] [Abstract][Full Text] [Related]
6. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2.
Hedrick JA; Watry D; Speiser C; O'Donnell P; Lambris JD; Tsoukas CD
Eur J Immunol; 1992 May; 22(5):1123-31. PubMed ID: 1315687
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
9. Human B and T lymphocytes have similar amounts of CD21 mRNA, but differ in surface expression of the CD21 glycoprotein.
Braun M; Melchers I; Peter HH; Illges H
Int Immunol; 1998 Aug; 10(8):1197-202. PubMed ID: 9723706
[TBL] [Abstract][Full Text] [Related]
10. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes.
Young LS; Dawson CW; Brown KW; Rickinson AB
Int J Cancer; 1989 May; 43(5):786-94. PubMed ID: 2469656
[TBL] [Abstract][Full Text] [Related]
11. Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV.
Luxembourg AT; Cooper NR
J Immunol; 1994 Nov; 153(10):4448-57. PubMed ID: 7525704
[TBL] [Abstract][Full Text] [Related]
12. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus envelope glycoprotein gp350 induces NF-kappaB activation and IL-1beta synthesis in human monocytes-macrophages involving PKC and PI3-K.
D'Addario M; Ahmad A; Xu JW; Menezes J
FASEB J; 1999 Dec; 13(15):2203-13. PubMed ID: 10593868
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.
Henchoz-Lecoanet S; Jeannin P; Aubry JP; Graber P; Bradshaw CG; Pochon S; Bonnefoy JY
Immunology; 1996 May; 88(1):35-9. PubMed ID: 8707347
[TBL] [Abstract][Full Text] [Related]
15. Redox control of EBV infection: prevention by thiol-dependent modulation of functional CD21/EBV receptor expression.
Nishinaka Y; Nakamura H; Okada N; Okada H; Yodoi J
Antioxid Redox Signal; 2001 Dec; 3(6):1075-87. PubMed ID: 11813981
[TBL] [Abstract][Full Text] [Related]
16. Infection of human thymocytes by Epstein-Barr virus.
Watry D; Hedrick JA; Siervo S; Rhodes G; Lamberti JJ; Lambris JD; Tsoukas CD
J Exp Med; 1991 Apr; 173(4):971-80. PubMed ID: 1706754
[TBL] [Abstract][Full Text] [Related]
17. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.
Hedrick JA; Lao Z; Lipps SG; Wang Y; Todd SC; Lambris JD; Tsoukas CD
J Immunol; 1994 Nov; 153(10):4418-26. PubMed ID: 7963519
[TBL] [Abstract][Full Text] [Related]
19. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
20. Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen.
Delsol G; Meggetto F; Brousset P; Cohen-Knafo E; al Saati T; Rochaix P; Gorguet B; Rubin B; Voigt JJ; Chittal S
Am J Pathol; 1993 Jun; 142(6):1729-38. PubMed ID: 7685151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
